BioAmber (BIOA) Tops Q1 EPS by 13c

BioAmber (NYSE: BIOA) reported Q1 EPS of $0.00, $0.13 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.12 million versus the consensus estimate of $4.02 million.

For earnings history and earnings-related data on BioAmber (BIOA) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease